| Literature DB >> 29386879 |
Marion Schroeder1, Ulrika Kjellström1.
Abstract
Purpose: To assess retinal function in combination with the retinal structure in ABCA4-associated retinal degenerations. Moreover, to evaluate the possibility of predicting the natural course of these disorders.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29386879 PMCID: PMC5757858
Source DB: PubMed Journal: Mol Vis ISSN: 1090-0535 Impact factor: 2.367
Demographic data, ABCA4 mutations, and ffERG results.
| 1/41/ | STGD | c.4773+3A>G (hom) | 86, 90 | 279,
268 | 430,
425 | 59,
61 | 31.0,
31.5 | 27,
23 |
| 2/71/ | STGD | c.2564 G>A
c.3113 C>T
c.4506 C>T | 13, 77 | 164,
159 | 283,
284 | 35,
41 | 38.0,
37.0 | 6,
9 |
| 3/27/ | STGD | c.1622 T>C
c.3113 C>T
c.5882 G>A | 44, 43 | 294,
299 | 488,
522 | 80,
81 | 27.0,
26.5 | 20.7,
23.7 |
| 4/48/ | STGD | c.5882 G>A
c.5917del | 74, 64 | 165,
144 | 356,
334 | 57,
55 | 28.5,
28.5 | 20.7, |
| 5/45/ | STGD | c.3113 C>T
c.768 G>T | 43, 44 | 195,
154 | 367,
315 | 59,
54 | 28.0,
27.5 | 12.4,
9.6 |
| 6/34/ | STGD | c.768 G>T
c.1610 G>A | N, N | 216,
230 | 320,
451 | 89,
96 | 27.5,
28.6 | N |
| 7/38/ | STGD | c.2915 C>A
c.5537 T>C | 39, 41 | 388,
306 | 657,
524 | 95,
83 | 30.0,
30.0 | 28.4,
21.7 |
| 8/18/ | STGD | c.868 C>T
c.317 A>T | N, N | 252,
238 | 348,
260 | 73,
49 | 27.0,
27.5 | 25.0,
24.8 |
| 9/32/ | STGD | c.3386 G>T (hom) | 68, 68 | 285,
224 | 433,
378 | 68,
64 | 31.0,
30.5 | 18.0,
24.7 |
| 10/22/ | STGD | c.5882 G>A
c.5917del | 39, 40 | 277,
230 | 371,
309 | 75,
60 | 27.5,
27.5 | 24.4 |
| 11/35/ | STGD | c.2588 G>C
c.4253+4 C>T | N, N | 269,
223 | 470,
369 | 87,
74 | 30.5,
30.5 | 11.3,
17.7 |
| 12/10/ | STGD | c.768 G>T (hom) | 49. 54 | 119,
N | 199,
N | 29,
N | 30.5,
N | 8.2,
N |
| 13/23/ | CRD | c.1622 T>C
c.3113 C>T
c.1804 C>T | 30, 25 | 48,
38 | 136,
N | 9,
11 | 46.0,
50.0 | 2.2,
N |
| 14/39/ | CRD | c.1933 G>T
c.4249_4 251del | N, N | 43,
65 | N,
N | 21,
32 | 40.0,
39.5 | 5,7
N |
| 15/29/ | CRD | c.5882 G>A
c.4773+1 G>A | 24, 21 | 17,
17 | 23,
18 | 2,
7 | 42.0,
39.6 | 1.3
1.7 |
| 16/40/ | CRD | c.286 A>G
c.1798 G>T | 15, 9 | 108,
116 | 215,
191 | 44,
61 | 35.0,
33.0 | 7.3,
10.3 |
| 17/41/ | STGD | c.768 G>T
c.6112 C>T | 6, 25 | 83,
103 | 153,
175 | 19,
24 | 36.0,
34.0 | 6.0,
9.3 |
| 18/40/ | STGD | c.2588 G>C
c.4253+4 C>T | N, N | 132,
81 | 241,
144 | 37,
24 | 35.0,
39.5 | 9.7,
9.3 |
| 19/27/ | CRD | c.634 C>T
c.5882 G>A | N, N | 81,
63 | 158,
123 | 19,
26 | 34.5,
34.0 | 8.6 |
| 20/28/ | CRD | c.1654 G>A
c.4363 T>C | 35, 35 | 38,
34 | 52,
57 | 4,
5 | 45.0,
42.5 | 1.0,
0.7 |
| 21/27/ | STGD | c.768 G>T (hom) | 13, 28 | 62,
42 | 71,
91 | 4,
4 | 42.0,
42.5 | 1.0,
1.3 |
| 22/16/ | CRD | c.319 C>T
c.5461–10 T>C | N, N | 69,
61 | 104,
85 | 7,
6 | 45.4,
45.5 | N,
1.7 |
| 23/20/ | CRD | c.768 G>T
c.2894 A>G | 20, 22 | 168,
144 | 225,
234 | 11,
13 | 42.1,
39.5 | 2.3,
2.3 |
| 24/16/ | STGD | c.1622 T>C
c.3113 C>T
c.1804 C>T | 11, 17 | 178,
170 | 452,
290 | 32,
35 | 36.0,
35.0 | 3.8,
N |
| 25/31/ | STGD | c.4773+1 G>A
c.53 G>A | 17, 22 | 101,
131 | 153,
181 | 16,
48 | 39.5,
39.0 | 2.0,
4.3 |
| 26/25/ | STGD | c.2894 A>G (hom) | 19, 24 | 143,
134 | 260,
280 | 31,
41 | 29.5,
28.5 | 8.7,
13.7 |
| 27/22/ | STGD | c.2894 A>G
c.4667+ T>C | 17, 36 | 162,
122 | 270,
214 | 59,
79 | 33.5,
33.0 | 3.8,
4.5 |
| 28/24/ | CRD | c.768 G>T
c.2894 A>G | 14, 23 | 145,
162 | 290,
252 | 23
27 | 38.0,
39.5 | N,
N |
| 29/62/ | STGD | c.1007 C>G
c.5714+ 5G>A | N, N | 33,
57 | N,
N | 9,
14 | 42.0,
42.0 | N,
N |
| 30/23/ | CRD | c. 5917 del (hom) | 17, 24 | 60,
75 | 101,
103 | 12,
13 | 40.0,
41.0 | N,
1.3 |
| 31/50/ | CRD | c.768 G>T
c.4253+ 4C>T | 4, 3 | 72,
70 | 104,
109 | 6,
7 | 41.2,
43.2 | 3.3,
1.7 |
| 32/40/ | CRD | c.3259 G>A (hom) | 0, 4 | 30,
4 | 40,
29 | 4,
2 | 43.5,
42.0 | Not measurable |
| 33/34/ | CRD | c.6229 C>T (hom) | 6, 16 | 39,
36 | 76,
67 | 9,
13 | 43.0,
43.5 | 5.7,
3.3 |
| 34/70/ | CRD | c.768 G>T c.2894 A>G | N, N | 10, 0 | N, N | 6, 7 | 41.0, 41.0 | N, N |
BVA=best corrected visual acuity, ETDRS=early treatment diabetic retinopathy study, RE=right eye, LE=left eye, Ampl=amplitude, µV=micro volt, IT=implicit time, ms=milliseconds, STGD=Stargardt disease, hom=homozygote, NRP=not registered previously, n=not performed, CRD=cone-rod dystrophy
Figure 1Examples of Goldmann visual field plots from one patient in each of the three groups. A: Typical Goldmann visual fields for group 1 with small central scotomas less than 10° (patient 10). B: Group 2 with larger central scotomas from 10° to 35° (patient 24). C: Typical for group 3 with temporal visual field residues (patient 30).
Figure 2Representative red-free and color fundus photographs of patients from the three groups. A and B: Patient 10 in group 1 shows subtle pigmentary irregularity in the macular region as in most patients in the group. C and D: Subject 24 in group 2 demonstrates a slightly pale optic disc, more widespread pigmentary changes in the posterior pole, as well as deep yellow flecks in the midperiphery; in this subject most apparent nasal and inferior of the optic nerve. More extensive flecks were encountered in some other subjects in the group. E and F: Patient 30 reveals a pale optic disc, narrow retinal vessels, extensive pigmentary changes in the macular region, and bone corpuscle pigmentations in the periphery.
Figure 3Representative autofluorescence images from one patient of each group. A and B: Patient 10 in group 1 shows reduced autofluorescence (AF) in the fovea with a surrounding ring of increased AF. Similar findings were encountered in all patients in group 1 except patient 1 who also demonstrated a pisciform pattern of increased and reduced AF beyond the central decreased AF. C and D: Patient 24 in group 2 shows a larger central area with the absence of AF surrounded by widespread mottling of increased and reduced AF. AF images from the other patients in group 2 are similar. E and F: Patient 30 in group 3 is in line with the other patients of the group demonstrating a large central area of absent AF, as well as widespread rounded flecks of reduced AF around the vascular arcades.
Full-field ERG results for the different groups and controls; means ± standard deviations.
| 1 | 252±69
225±58 | 212±44
205±51 | 405±107
380±96 | 69±17
64±17 | 29.6±3.3
29.3±3.2 | 30.0±2.3
30.0±3.4 |
| 2 | 105±63
105±54 | 96±61
90±55 | 204±124
180±96 | 25±22
31±25 | 37.9±5.3
34.1±4.8 | 35.1±5.7
36.8±6.1 |
| 3 | 42±25
46±33 | 30±10
33±9 | 80±30
76±37 | 7±3
8±5 | 41.7±1.5
42.1±1.2 | 42.8±2.0
43.3±3.1 |
| controls | 247±59 223±58 | 217±52 198±50 | 407±89 350±85 | 65±22 58±16 | 29.9±1.6 29.5±1. |
Amp=amplitude, RE=right eye, LE=left eye, IT=implicit time, first time=first ffERG measurement in the patients that had a previous ffERG registration
Means and standard deviations (SDs) for mERG amplitudes in rings 1–5 of each eye in the three groups of subjects as well as the p values for the Kruskal–Wallis test. For comparison, the bottom row shows means and SDs for mERG amplitudes in controls.
| 1 | 16±6
15±7 | 14±6
13±5 | 15±6
13±5 | 16±6
15±6 | 17±6
17±6 |
| 2 | 7±3
8±4 | 5±2
6±5 | 4±2
5±3 | 4±2
5±3 | 4±3
5±4 |
| 3 | 5±2
5±2 | 5±3
6±5 | 4±2
4±3 | 3±2
3±2 | 2±0,5
2±1 |
| P value Kruskal–Wallis test | |||||
| controls | 51±15 46±12 | 35±10 33±8 | 29±8 27±6 | 25±6 23±6 | 24±7 23±6 |
Ampl=amplitude, RE=right eye, LE=left eye
p values for the Mann–Whitney U-test comparing mERG amplitudes of the different mERG rings in group 1–3 to the normal material. Significant p values are in italics.
| 1 RE | |||
| 2 RE | |||
| 3 RE | |||
| 4 RE | |||
| 5 RE | |||
| | | | |
| 1 LE | |||
| 2 LE | |||
| 3 LE | |||
| 4 LE | |||
| 5 LE | 0,121 |
RE=right eye, LE=left eye
Figure 4OCT images of one representative patient from each group. A: Loss of the photoreceptor integrity line (PIL; indicated by the white brace) in the macular region in patient 10 from group 1. The PIL corresponds to the junction of the inner and outer segments of the photoreceptors. The same pattern was encountered in all but two patients in group 1. One of those two patients showed more extensive PIL loss, and the other had better preserved but disorganized PIL. B: Representative total PIL loss and RPE atrophy in patient 24 from group 2. All but one patient in group 2 showed the same optical coherence tomography (OCT) changes. Patient 19 had a defect PIL in the center but a preserved PIL beyond this. C: Patient 30 from group 3 also shows total PIL loss and extensive RPE atrophy as observed in the other patients in group 3.